NCT05163405View on ClinicalTrials.gov

Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

January 1, 2022

Study Completion Date

June 1, 2022

Conditions
Multiple Myeloma
Interventions
DRUG

Bortezomib

Self-administration of subcutaneously Velcade.

Trial Locations (1)

5000

Odense University Hospital, Odense

All Listed Sponsors
lead

Karin B. Ø. Dieperink

OTHER

NCT05163405 - Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma. | Biotech Hunter | Biotech Hunter